Mutual concessions and compromises between stromal cells and cancer cells: driving tumor development and drug resistance

ConclusionsThis review presents a holistic view on the translational potential of the interplay between stromal cells and cancer cells. This interplay is currently being employed for the development of promising preclinical and clinical biomarkers, and the design of small molecule inhibitors, antibodies and small RNAs for (combinatorial) cancer treatment options. In addition, nano-carriers, tissue scaffolds and 3-D based matrices are being developed to precisely and safely deliver these compounds.
Source: Cellular Oncology - Category: Cancer & Oncology Source Type: research